CU6.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 mai 2024 @ 08:10):

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults...

Stats
Dagens volum	2.95M
Gjennomsnittsvolum	999 191
Markedsverdi	1.38B
EPS	$0 ( 2023-08-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-42.33
ATR14	$0.0180 (0.36%)

Volum Korrelasjon

Lang: 0.07 (neutral)

Kort: 0.20 (neutral)

Signal:(46.366) Neutral

Clarity Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Clarity Pharmaceuticals Korrelasjon - Valuta/Råvare

0.18
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.16
( neutral )

-0.17
( neutral )

-0.22
( neutral )

Clarity Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$9.80M
Bruttogevinst:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2023
Omsetning:	$9.80M
Bruttogevinst:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2022
Omsetning:	$6.46M
Bruttogevinst:	$6.41M (99.28 %)
EPS:	$-0.0956

Financial Reports:

No articles found.

Clarity Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.